Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

SML2073

Sigma-Aldrich

(R)-9bMS

≥98% (HPLC)

Synonym(s):

(R)-5-Chloro-N-[4-(4-methylpiperazin-1-yl)phenyl]-N′-[(tetrahydrofuran-2-yl)methyl]pyrimidine-2,4-diamine mesylate, (R)-9b mesylate, 5-Chloro-N2-[4-(4-methyl-1-piperazinyl)phenyl]-N4-[[(2R)-tetrahydro-2-furanyl]methyl]-2,4-pyrimidinediamine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H31ClN6O4S
CAS Number:
1655527-68-6
Molecular Weight:
499.03
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

C[N+](CC1)([H])CCN1C(C=C2)=CC=C2NC3=NC(NC[C@@H]4OCCC4)=C(Cl)C=N3.CS(=O)([O-])=O

Biochem/physiol Actions

(R)-9bMS is a potent and selective inhibitor of ACK1 (TNK2) tyrosine kinase that exhibits potent anticancer activity. (R)-9bMS attenuates AR and AR-V7 expression in prostate cancer cells. (R)-9bMS potently inhibits triple negative breast cancer (TNBC) cells proliferation.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Harshani R Lawrence et al.
Journal of medicinal chemistry, 58(6), 2746-2763 (2015-02-24)
The tyrosine kinase ACK1, a critical signal transducer regulating survival of hormone-refractory cancers, is an important therapeutic target, for which there are no selective inhibitors in clinical trials to date. This work reports the discovery of novel and potent inhibitors
Kiran Mahajan et al.
Cancer cell, 31(6), 790-803 (2017-06-14)
The androgen receptor (AR) is critical for the progression of prostate cancer to a castration-resistant (CRPC) state. AR antagonists are ineffective due to their inability to repress the expression of AR or its splice variant, AR-V7. Here, we report that
Xinyan Wu et al.
Oncotarget, 8(2), 2971-2983 (2016-12-03)
Breast cancer is the most prevalent cancer in women worldwide. About 15-20% of all breast cancers do not express estrogen receptor, progesterone receptor or HER2 receptor and hence are collectively classified as triple negative breast cancer (TNBC). These tumors are

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service